Ignite Creation Date:
2024-07-17 @ 11:12 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06491225
Status:
RECRUITING
Last Update Posted:
2024-07-09
First Post:
2024-06-30
Brief Title:
Autologous Tumor-Infiltrating Lymphocyte GTE-001 Injection for Treatment of Patients With Advanced Lung Adenocarcinoma
Sponsor:
Grit Biotechnology
Organization:
Grit Biotechnology
Study Overview
Official Title:
A Phase I Open Label Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-Infiltrating Lymphocyte GTE-001 Injection for Treatment of Patients With Advanced Lung Adenocarcinoma
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a Multiple centers open design aimed at evaluating the safetyefficacy and Production feasibility of Autologous Tumor-Infiltrating Lymphocyte GTE-001 injection for treatment of patients with Advanced lung adenocarcinomaAnd evaluate potential biomarkers related to GTE-001 activity
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None